MAPS Archives -

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp

MDMA on track for 2023 approval as PTSD therapy, says developer

https://pharmaphorum.com/news/mdma-on-track-for-2023-approval-as-ptsd-therapy-says-developer/

The bar is set high for Medical Affairs (MA) talent: traditional capabilities are no longer sufficient to address

Leadership: Cultivating a Culture of High Curiosity

https://pharmaphorum.com/partner-content-market-access/leadership-cultivating-a-culture-of-high-curiosity/

The Medical Affairs Professionals Society (MAPS) presents its inaugral European conference this year, created by medical affairs professionals,

MAPS 2018 EMEA Annual Meeting

https://pharmaphorum.com/partner-content/events-partner-content/maps-2018-emea-annual-meeting/

A number of trends including tougher regulatory controls, increased transparency expectations, an increasingly vocal patient and greater requirements

Cementing the Value of Medical Affairs

https://pharmaphorum.com/views-analysis-sales-marketing/cementing-value-medical-affairs/

US non-profit organisation to begin late-stage trials this year

FDA names MDMA a ‘breakthrough’ for post-traumatic stress

https://pharmaphorum.com/news/fda-backs-late-stage-trial-mdma-post-traumatic-stress/

Kirk Shepard, Eisai’s SVP of Global Medical Affairs Oncology, talks about how his profession has developed hugely in

Medical Affairs – the heart of a data-driven, patient-centric pharma

https://pharmaphorum.com/views-and-analysis/medical-affairs-heart-data-driven-patient-centric-pharma/

MAPS